KSPHF (Kissei Pharmaceutical Co) ROCE % : 2.73% (As of Sep. 2024)

View and export this data going back to 2016. Start your Free Trial

What is Kissei Pharmaceutical Co ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Kissei Pharmaceutical Co's annualized ROCE % for the quarter that ended in Sep. 2024 was 2.73%.

Kissei Pharmaceutical Co ROCE % Historical Data

The historical data trend for Kissei Pharmaceutical Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kissei Pharmaceutical Co ROCE % Chart

Kissei Pharmaceutical Co Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

ROCE %

Get a 7-Day Free Trial

2.28

3.21

6.71

6.04

6.10

Kissei Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															5.83	6.85	5.79	8.62	2.73

Kissei Pharmaceutical Co ROCE % Calculation

Kissei Pharmaceutical Co's annualized ROCE % for the fiscal year that ended in Mar. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2024 )		(A: Mar. 2023 )		(A: Mar. 2024 )
	=	96.563	/	( ( (1654.892 - 111.9)	+	(1741.633 - 117.896) )	/ 2 )
	=	96.563	/	( (1542.992	+	1623.737)	/ 2 )
	=	96.563	/	1583.3645
	=	6.10 %

Kissei Pharmaceutical Co's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	45.972	/	( ( (0 - 0)	+	(1821.138 - 136.044) )	/ 1 )
	=	45.972	/	( ( 0	+	1685.094 )	/ 1 )
	=	45.972	/	1685.094
	=	2.73 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Kissei Pharmaceutical Co (OTCPK:KSPHF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Kissei Pharmaceutical Co ROCE % Related Terms

Thank you for viewing the detailed overview of Kissei Pharmaceutical Co's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kissei Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kissei Pharmaceutical Co Ltd (OTCPK:KSPHF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

4547:Japan

Address

19-48, Yoshino, Matsumoto City, Nagano, JPN, 399-8710

Website

http://www.kissei.co.jp

Kissei Pharmaceutical Co Ltd is a specialty and generic drug manufacturing company. Pharmaceuticals is the company's reportable segment. The company's operations span across the globe, while the vast majority of revenue is generated in Japan, followed by Europe. Kissei operates a variety of subsidiaries. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.